Last reviewed · How we verify
Metronidazole Topical Gel 1%
At a glance
| Generic name | Metronidazole Topical Gel 1% |
|---|---|
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of Transdermal Metronidazole (PHASE4)
- Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris (PHASE4)
- Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo (PHASE4)
- An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%
- A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea (PHASE3)
- Preferences & Treatment Satisfaction Drivers in Rosacea Patients
- Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea (PHASE4)
- LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole Topical Gel 1% CI brief — competitive landscape report
- Metronidazole Topical Gel 1% updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI